mika wird in Deutschland entwickelt und alle Daten werden anonymisiert und nach höchsten Sicherheitsstandards auf Servern in Deutschland gespeichert. Unser Geschäftsmodell ist ausdrücklich nicht die Weitergabe von Patienteninformationen. Wir möchten Menschen in der Krebstherapie einen Dienst bieten, der ihnen eine echte Hilfe ist.
VivoSense, also known as Vivonoetics are a data analysis and software company specializing in wearable sensor physiological monitoring solutions for research and clinical trials.
Nucleai Ltd. develops AI-powered pathology platform that is used for satellite image analysis to detect cancer, prostate, breast, and gastrointestinal related diseases. Its platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy, and improving patient care. It serves hospitals and labs in in the United States and Israel. The company was founded in 2017 and is headquartered in Tel Aviv-Yafo, Israel.
VeriSIM Life, Inc. develops disease-specific biosimulation models that allow researchers at pharmaceutical companies to model in software how a drug will interact in animals. The company was incorporated in 2017 and is based in San Francisco, California.
Mekonos Inc. engages in the design, development, and production of gene and cell therapies. The company develops integrated system-on-a-chip to develop predictive models for discovery and development. It develops MEMS, a technology that allows controlling individual nanoneedles to inject single cells, in a parallel architecture. Also, the company operates a cell-engineering platform. The company was founded in 2017 and is based in San Francisco, California
Carevive Systems provides personalized and dynamic cancer care plans for patients that improve clinical outcomes and enable oncology practices to operate in emerging value-based models. Its care plans continuously update to provide ongoing guidance to patients based on their experiences throughout the journey. Located in North Miami, Florida.
Voluntis, Inc. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. It offers Insulia, a prescription-only medical device that provides type 2 diabetes patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Voluntis, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Oncomfort SA specializes in developing innovative digital sedation solutions aimed at alleviating pain and anxiety in patients undergoing medical procedures. Founded in 2017 and based in Wavre, Belgium, the company offers Sedakit, a portable, all-in-one device that delivers digital sedation therapy. This therapy integrates clinical hypnotherapy and various therapeutic techniques through virtual reality, providing a non-pharmacological approach to managing anxiety and discomfort. By utilizing evidence-based methods, Oncomfort's technology enhances patient comfort throughout their medical journey, addressing the psychological and emotional challenges associated with medical treatments.
Nucleai Ltd. develops AI-powered pathology platform that is used for satellite image analysis to detect cancer, prostate, breast, and gastrointestinal related diseases. Its platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy, and improving patient care. It serves hospitals and labs in in the United States and Israel. The company was founded in 2017 and is headquartered in Tel Aviv-Yafo, Israel.
Carevive Systems provides personalized and dynamic cancer care plans for patients that improve clinical outcomes and enable oncology practices to operate in emerging value-based models. Its care plans continuously update to provide ongoing guidance to patients based on their experiences throughout the journey. Located in North Miami, Florida.
novadiscovery is a developer of a drug discovery platform in silico clinical trials designed to de-risk, optimize research and development along with curbing the cost of discovering new drugs. The company's platform uses mathematics and intelligent algorithms to build a community of virtual patients as on-demand digital lab rats, enabling scientists and biotech, pharma companies to predict drug efficacy and create the target combination.
BC Platforms provides powerful genomic data management solutions to address some of the biggest healthcare challenges by leveraging the convergence of genomics and IT. Our high-performing data management platform enables flexible data integration, secure analysis and interpretation of molecular information and clinical big data in a systematic and standardized manner.
Little Green House have a vision to make our daycare a place where everyone is free to be who they are and to become who they want to be.
Kaiku Health Oy develops and delivers user-centered software solutions for patients, doctors, and nurses to communicate online. It develops a communication and follow-up solution for cancer patients to communicate with medical staff in Swedish, English, German, and Finnish languages. The company serves clinics and university hospitals in Finland, Sweden, and Switzerland. Kaiku Health Oy was formerly known as Netmedi Oy and changed its name to Kaiku Health Oy in September 2017. The company was founded in 2012 and is based in Helsinki, Finland. As of May 15, 2020, Kaiku Health Oy operates as a subsidiary of Elekta AB (publ).
ABAC Therapeutics S.A. develops precision antimicrobial agents for precision treatment of MDR Gram-negative infections. It offers PasNas, a drug discovery platform unveiling pathogen-specific antibacterial properties of molecules while promoting the compounds active against MDR strains with new mechanism of action and with maximized chances of success in clinical development. The company was incorporated in 2014 and is based in Barcelona, Spain. As of November 20, 2019, ABAC Therapeutics S.A. operates as a subsidiary of Tibidabo Ventures.
BC Platforms provides powerful genomic data management solutions to address some of the biggest healthcare challenges by leveraging the convergence of genomics and IT. Our high-performing data management platform enables flexible data integration, secure analysis and interpretation of molecular information and clinical big data in a systematic and standardized manner.
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.
BPA Solutions SA specializes in providing innovative business applications that enhance Microsoft SharePoint and Office 365. Founded in 2001 and headquartered in Yverdon-les-Bains, Switzerland, the company develops a range of solutions including BPA CRM for customer relationship management, BPA Quality for quality management, and BPA Risk for tracking business activities in complex environments. Additional offerings include BPA Project for project management, BPA Recruiting for candidate management, and Self-Service tools for process sharing. BPA Solutions also features a Solutions Suite to monitor critical business processes and mobile solutions, along with professional services such as training, consulting, and support. The company delivers its software on-premise, through private or Microsoft clouds, and in hybrid environments, serving clients globally.
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.
Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.
KeyLemon S.A. develops face recognition technology. The company was founded in 2008 and is based in Martigny, Switzerland. As of February 22, 2018, KeyLemon S.A. operates as a subsidiary of ams AG.
Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.
Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or join in with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn...
Compliant Concept is a spinoff of the Empa and the ETH Zurich. They develop intelligent bed systems for the treatment and prevention of pressure ulcers.
compliant concept is a spin-off of ETH Zurich and Empa, with its roots in Empa's Laboratory for Mechanics for Modeling and Simulation.
Their goal is to make the care of hospital patients and nursing home residents safer, more efficient and more comfortable.
Spinomix is a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector. Based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is building the new gold standard for the processing of biochemical substances. Its products capture and extract samples at a quality and efficiency far superior to current practice, thus enabling more efficient diagnostics. The company’s main focus is on applications which are critical for treatment decisions in a variety of human diseases. Other applications target markets such as animal health and food safety. Spinomix’ products MagPhase™ and FibroTrap™ improve the accuracy and time taken to obtain meaningful results from samples that are highly heterogeneous and notoriously difficult to analyse (e.g. blood, urine, swabs and food matrices). Today many aspects of sample processing are still labour and time intensive. Therefore, there is a significant opportunity for Spinomix’s technologies to streamline the process. They are targeting double-digit growth markets such as nucleic acids extraction, believed to be worth $2 billion; cell separation growing to over $2.5 billion; food safety at over $2 billion; and molecular diagnostics for infectious diseases estimated at $2.7 billion. Their current approach is to concentrate on product innovation and market validation. They have collaboration agreements in place and are conducting validation programs of their products with key market players in research and industry. Their goal is to develop these collaborations into strategic commercial partnerships to license their products.
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.
Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.
Searchbox is a software company specializing in search technologies, with strong areas of expertise in cognitive sciences, data mining and computer sciences. Through its innovative technologies, Searchbox fundamentally changes the way people interact and consume information. Through highly customizable cloud based search solutions and plugins for Solr, these technologies are readily available for usage with a minimal amount of tinkering.
Tweasy helps businesses stay close to their customers and grow strong and profitable relationships. The Tweasy application brings together all the news, promotions, surveys and information generated by businesses, clubs and associations to help them communicate.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Private Equity Round in 2012
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.
Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Based in Lexington, Massachusetts, Curis is advancing several clinical-stage drug candidates, including CA-4948, an oral small molecule currently in Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia, and Fimepinostat, which targets specific enzymes for MYC-altered diffuse large B-cell lymphoma. The company also has additional pipeline products such as CA-170 for advanced solid tumors and CA-327, which is in the pre-investigational new drug stage. Curis collaborates with notable partners like F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development of Erivedge, a small molecule designed to inhibit the hedgehog signaling pathway in advanced basal cell carcinoma, among other partnerships aimed at enhancing immuno-oncology and precision oncology efforts. Founded in 2000, Curis aims to leverage its expertise in signaling pathways to create targeted cancer therapies.
Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are
widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.